Bristol-Myers Squibb Company (BMY)

Outperform Current rating · 3 reports

Coverage summary

Aardvark Labs Capital Research has covered Bristol-Myers Squibb Company (BMY) since May 1, 2026. The company is in the Healthcare sector. This page lists 3 reports: 3 earnings recaps.

The latest is the Q3 2026 Earnings Recap, published November 1, 2026. That report moved the rating from Hold to Outperform. The rating has changed once since coverage began.

Translations: 2 in Chinese.

Rating history

May 1, 2026 First rating: Hold Q1 2026 Earnings Recap
November 1, 2026 Hold → Outperform Q3 2026 Earnings Recap

All BMY reports

2026-11-01

Outperform Recap: Q3 2026

Four Registrational Wins, a Higher Estimate and a Lower Price: Upgrading Bristol Myers to Outperform

2026-07-31

Hold Recap: Q2 2026

Eliquis Rewrites the 2026 Guide While Underlying EPS Sits Flat and Two Flagship Readouts Slip to 2027

2026-05-01

Hold Recap: Q1 2026

Growth Portfolio Clears Half of Revenue While EPS Falls 12%: Initiating Bristol Myers Squibb at Hold Ahead of a Binary Second Half